SCHEDULE: Capital World Investors Reports 8.2% Stake in Alnylam Pharma

Capital World Investors has disclosed a beneficial ownership of 10,916,799 shares, representing 8.2% of the outstanding common stock of Alnylam Pharmaceuticals, Inc.

Summary

• Capital World Investors (CWI) has filed a Schedule 13G, indicating their beneficial ownership of Alnylam Pharmaceuticals, Inc. common stock.
• As of March 31, 2026, CWI holds 10,916,799 shares, which constitutes 8.2% of the total outstanding shares.
• CWI has sole voting power over 10,871,837 shares and sole dispositive power over all 10,916,799 shares.
• The filing confirms that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating substantial institutional interest and confidence in Alnylam Pharmaceuticals, Inc. without any immediate negative implications.

Positives

• Significant institutional ownership by Capital World Investors, a well-established investment management entity.
• The filing indicates a passive investment approach, suggesting confidence in Alnylam's long-term prospects without seeking control.

Risks

• While not explicitly stated as a risk in this filing, significant institutional holdings can sometimes lead to increased share price volatility if the institution decides to divest.
• The filing does not provide details on the specific investment strategy or rationale behind acquiring this stake, leaving room for speculation.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from Alnylam Pharmaceuticals, Inc.

Industry Context

StockSavvy.ai notes that significant filings like this Schedule 13G from major institutional investors such as Capital World Investors often signal sustained confidence in a company's long-term strategy and market position within the biotechnology sector.

Stakeholder Impact

• Shareholders may view the increased institutional ownership by a reputable firm like Capital World Investors as a positive signal, potentially increasing demand for the stock.
• The passive nature of the investment suggests no immediate impact on corporate control or strategic direction from this specific filing.

Key Dates

Keywords

Alnylam Pharmaceuticals, Capital World Investors, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management